Search

Trihexyphenidyl

[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.

Varicella zoster vaccine (live/attenuated)

First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles. … PHN can last for days, months, or even years following resolution of shingles.

Sodium tetradecyl sulfate

An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.

Xenon-133

Xenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.

DL-alpha tocopheryl acetate

Enflurane

Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market. Unlike its other inhalational anesthetic counterparts including isoflurane and halothane...

Cyclobenzaprine

[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. … Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977.

Potassium nitrate

Potassium nitrate is an inorganic salt with a chemical formula of KNO3. … It is a natural source of nitrate and has been used as a constituent for several different purposes, including food preservatives, fertilizers, tree stump removal, rocket propellants, and fireworks.

Tegaserod

Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). … [L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically

Pemigatinib

With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.